Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Palatin Technologies Inc (PTN)
NYSE MKT:PTN
Palatin Technologies (PTN) Stock Price & Analysis
2,774 Followers
PTN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.43 - $5.65
Previous Close$1.77
Volume88.61K
Average Volume (3M)140.65K
Market Cap
$28.56M
Enterprise Value$30.30M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$1.74M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Sep 12, 2024EPS Estimate
-$0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.49
Shares Outstanding16,136,640
10 Day Avg. Volume92,324
30 Day Avg. Volume140,645
Standard Deviation0.25
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)19.32
Price to Sales (P/S)6.28
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.47
Enterprise Value/Gross Profit6.83
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$8.67Price Target Upside373.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Palatin Technologies News
PremiumCompany Announcements
Palatin Technologies Secures Growth with Warrant Exercise Deal
PremiumPre-Earnings
Is PTN a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Clinical TrialsPalatin kick-starts Phase 2 combo trial for erectile dysfunction with a new co-formulation that can be administered as a single injection.
Market PotentialED represents a substantial market characterized by significant unmet medical needs among patients who are unresponsive to PDE5 inhibitors.
Obesity TreatmentCombining the company’s melanocortin receptor 4 (MCR4) agonist with FDA-approved dual GLP-1/GIP receptor agonists to treat obesity shows potential.
Bears Say
Clinical TrialsThe PL9643 MELODY-1 Phase 3 trial in dry eye disease failed to reach statistical significance on the co-primary endpoints.
EarningsPalatin posted F3Q’24 earnings including EPS of -$0.53 vs. consensus of -$0.45 and estimate of -$0.48.
Financial PerformanceWith less than six months’ cash while starting two Phase 2s near-term and two Phase 3s by year-end, analysts are reducing the price target from $5 to $3 given expectations.
---
Ownership Overview
75.05% Insiders
4.64% Mutual Funds
3.76% Other Institutional Investors
16.55% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PTN FAQ
What was Palatin Technologies Inc’s price range in the past 12 months?
Palatin Technologies Inc lowest stock price was $1.43 and its highest was $5.65 in the past 12 months.
What is Palatin Technologies Inc’s market cap?
Currently, no data Available
When is Palatin Technologies Inc’s upcoming earnings report date?
Palatin Technologies Inc’s upcoming earnings report date is Sep 12, 2024 which is in 56 days.
How were Palatin Technologies Inc’s earnings last quarter?
Palatin Technologies Inc released its earnings results on May 15, 2024. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.447 by -$0.083.
Is Palatin Technologies Inc overvalued?
According to Wall Street analysts Palatin Technologies Inc’s price is currently Undervalued.
Does Palatin Technologies Inc pay dividends?
Palatin Technologies Inc does not currently pay dividends.
What is Palatin Technologies Inc’s EPS estimate?
Palatin Technologies Inc’s EPS estimate is -$0.48.
How many shares outstanding does Palatin Technologies Inc have?
Palatin Technologies Inc has 16,136,648 shares outstanding.
What happened to Palatin Technologies Inc’s price movement after its last earnings report?
Palatin Technologies Inc reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.447. Following the earnings report the stock price went down -14.108%.
Which hedge fund is a major shareholder of Palatin Technologies Inc?
Among the largest hedge funds holding Palatin Technologies Inc’s share is Fortress Investment Group LLC. It holds Palatin Technologies Inc’s shares valued at 658.
---
Palatin Technologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (373.77% Upside)
$8.67 (373.77% Upside)
Blogger Sentiment
Bullish
PTN Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.54%
12-Months-Change
Fundamentals
Return on Equity
-588.69%
Trailing 12-Months
Asset Growth
-55.46%
Trailing 12-Months
Company Description
Palatin Technologies Inc
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
---
PTN Earnings Call
Q3 2024
0:00 / 0:00
---
PTN Stock 12 Month Forecast
Average Price Target
$8.67
▲(373.77% Upside)
Technical Analysis
Best Analysts Covering PTN
1 Year
1 Year Success Rate
6/24 ratings generated profit
1 Year Average Return
-28.12%
reiterated a buy rating 2 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -28.12% per trade.
---